HIV-positive newborns who begin antiretroviral therapy within hours or days after birth have better preserved immune systems and a much smaller viral reservoir—the hidden pool of virus that can rebound after treatment is stopped—than human immunodeficiency virus (HIV)-positive infants who start treatment at a more typical four months of age, according to a new study.
In Botswana, where the study was conducted, about 24 percent of all women are HIV-positive, and an estimated 300-500 babies are infected with the virus every day in sub-Saharan Africa, according to a November 27, 2019 Reuters article.
The result is a huge health care and human burden. “Without treatment, 50 percent of HIV-infected children progress to death within two years,” said study co-author Dr. Roger Shapiro, associate professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health.
Next year, the research team hopes to enroll some of the children in a trial in which they’d receive protective antibodies specifically engineered to neutralize the HIV virus, which could help them control their infections without the need for lifelong treatment.
Two other Harvard Chan School researchers — Gbolahan Ajibola, a study coordinator at the Botswana-Harvard AIDS Institute Partnership, and Ms. Kathleen Powis, research associate in the Department of Immunology and Infectious Diseases — were co-authors of the study.Tags: Friday Letter Submission, Publish on December 13